Ikarovec is a pre-clinical gene therapy company developing targeted treatments for diabetic macular edema and other common eye diseases through gene transfer techniques that introduce therapeutic DNA into ocular cells. This approach aims to provide long-lasting benefits with a single injection, reducing the need for frequent treatments and addressing the risk of vision loss.
Funding
$42.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for common eye diseases, such as diabetic macular edema and age-related macular degeneration, often require frequent injections or daily eye drops, posing challenges for long-term patient compliance and potentially leading to inconsistent therapeutic benefits. These conventional therapies typically target only a single disease pathway, limiting their overall efficacy in addressing the multifactorial nature of these conditions.
Solution
Ikarovec is developing gene therapies designed to address prevalent eye diseases through a single injection. Their approach involves introducing therapeutic DNA into ocular cells via gene transfer, instructing these cells to produce proteins that combat the disease. This single-administration method aims to provide sustained therapeutic effects, reducing the burden of frequent treatments. The gene therapies are engineered to target multiple disease pathways simultaneously, potentially enhancing efficacy compared to single-target drugs. Ikarovec's lead programs focus on geographic atrophy and neovascular age-related macular degeneration, with earlier-stage programs targeting diabetic macular edema and ocular hypertension.
Target Audience
The primary target audience includes patients suffering from common eye diseases such as diabetic macular edema, geographic atrophy, neovascular age-related macular degeneration, and ocular hypertension.
Features
- Gene transfer technology for targeted delivery of therapeutic DNA to ocular cells
- Single-injection administration for long-lasting therapeutic benefits
- Multi-target approach to address multiple disease pathways simultaneously
- Pre-clinical programs focused on geographic atrophy and neovascular (wet-form) age-related macular degeneration
- Earlier stage programs in diabetic macular edema and ocular hypertension